AstraZeneca (NYSE:AZN) has been backed in to a corner, but it looks as though the drug maker is ready to come out swinging. The company's stock price has gone nowhere over the last 10 years and it is set to face an onslaught of competition from generics in the coming years. However, a new CEO could give AstraZeneca the spark that it needs.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Up Against the Clock
Last week the company named its CFO as its interim CEO following the resignation of David Brennan who had faced a growing amount of criticism from investors. The role will not be an easy one to fill in the wake of demands from analysts and investors who are calling for the company to do deals larger than those that were transacted on Brennan's watch.

One of the greatest challenges facing AstraZeneca in the intermediate term is the expiration of patents on some of its biggest selling drugs. Nexium, which accounted for around 13% of the company's product revenue last year, is set to lose its patent protection in the United States in 2014. The company has already seen sales of the drug in Western Europe plummet due to generic competition.

AstraZeneca will have patent protection until late 2016 on its Seroquel XR. However, protection for its Seroquel IR formulation has already expired. XR accounted for roughly 12.9% of the company's product revenue in 2012 while IR comprised only about 4.4%.

SEE: Evaluating Pharmaceutical Companies

Looking Ahead
Now AstraZeneca is charged with hiring a CEO with thick skin who is either capable of pulling off a major acquisition or communicating the wisdom to the market on why smaller-sized deals make sense for the drug maker's long-term growth. Both challenges will be daunting, but can be overcome. AstraZeneca has been proactive in seeking out partnerships in the biotech space to develop new drug candidates as evidenced by its recent agreement with Amgen (Nasdaq:AMGN). It also has about $7.6 billion in cash at its disposal.

It may be too early to speculate on possible deals that could materialize down the road after a permanent CEO is hired, but analysts have already thrown out some ideas. Forest Laboratories (NYSE:FRX) and Amylin Pharmaceuticals (Nasdaq:AMLN) are two possible candidates. It has been reported by Reuters that Amylin has already begun the process of seeking out suitors.

The Bottom Line
It has been a very tough landscape for the major pharmaceutical companies as generics have become more commonplace and new drug approvals from the FDA have not gotten any easier. AstraZeneca faces these same challenges, but it has the opportunity to do something big when it brings in a new CEO. Whether the company decides to make a major acquisition or a series of smaller deals, it is going to need to remain aggressive if it wants to remain a major force among the top drug makers.

SEE: Analyzing An Acquisition Announcement

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Billy Fisher did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center